NDA 020547 · Strides Pharma Intl
Accolate
Zafirlukast · Oral · Leukotriene Receptor Antagonist
NovelLast checked: Nov 19, 2026Latest source record: Mar 29, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Sep 26, 1996
Approved uses
3
Original approval plus efficacy supplements
Registered trials
6
1 Phase 3, 0 recruiting
FAERS reports
907
477 serious, 44 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 16, 2026.
INDICATIONS AND USAGE Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.
Therapeutic areas: Respiratory
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 27, 2001 Supplement 14 · Efficacy Letter
- Sep 17, 1999 Supplement 7 · Efficacy ReviewLetter
- Sep 26, 1996 Original approval · Type 1 - New Molecular Entity Review
2 products under this application
- ACCOLATE · ZAFIRLUKAST 10MG · TABLET, ORAL · Prescription · TE AB
- ACCOLATE · ZAFIRLUKAST 20MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Zafirlukast" as an intervention, any sponsor and status, largest first.
- A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term TherapyPivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT01125748 · 176 participants · Start May 2010 · Primary completion Aug 2013
Drug: Omalizumab; Placebo and 1 more · For: Allergic Asthma
Sites: Huntsville, Alabama; Little Rock, Arkansas; Bakersfield, California · 100 sites in all
- The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19)Pivotal-lookingStatus unknown
King Abdullah International Medical Research CenterAcademic, hospital or other
NCT04871828 · 66 participants (planned) · Start Feb 28, 2021 · Primary completion Sep 2021
Drug: Leukotriene Receptor Antagonist · For: Moderate Covid19
Sites: Riyadh, Saudi Arabia
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01283061 · 44 participants · Start Dec 2007 · Primary completion Jan 2008
Drug: Zafirlukast · For: Healthy
Sites: Ahmedabad, India
- Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander ChallengeNot yet recruiting
Allergy & Asthma Medical Group & Research CenterAcademic, hospital or other
NCT06069063 · 12 participants (planned) · Start Dec 5, 2025 · Primary completion Jun 2026
Drug: Zafirlukast · For: Allergy to Cats
Beth Israel Deaconess Medical CenterAcademic, hospital or other
NCT04339140 · 5 participants · Start Jun 24, 2020 · Primary completion Dec 31, 2023
Drug: Zafirlukast · For: Ovarian Cancer
Sites: Boston, Massachusetts
University of California, San FranciscoAcademic, hospital or other
NCT02950480 · 4 participants · Start Mar 13, 2017 · Primary completion Dec 20, 2018
Drug: zafirlukast · For: Breast Cancer
Sites: San Francisco, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea110
- asthma96
- fatigue87
- drug ineffective65
- cough56
- nausea51
- pruritus49
- off label use48
- wheezing48
- headache47
- rash47
- pneumonia46
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 18 |
| 2005 | 10 |
| 2006 | 7 |
| 2007 | 9 |
| 2008 | 13 |
| 2009 | 14 |
| 2010 | 15 |
| 2011 | 14 |
| 2012 | 27 |
| 2013 | 25 |
| 2014 | 32 |
| 2015 | 38 |
| 2016 | 77 |
| 2017 | 51 |
| 2018 | 60 |
| 2019 | 51 |
| 2020 | 64 |
| 2021 | 68 |
| 2022 | 56 |
| 2023 | 53 |
| 2024 | 67 |
| 2025 | 83 |
| 2026 | 55 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: Systematic review and meta-analysis of randomized clinical trials.
Rayner DG, Liu M, Chu AWL, et al. · J Allergy Clin Immunol 2024 · Systematic Review, Meta-Analysis
- Efficacy and safety of Zafirlukast ('Accolate') in the management of patients with mild-to-moderate asthma.
Chukwu C, Okpapi J, Ige MO, et al. · West Afr J Med 2000 · Clinical Trial, Controlled Clinical Trial
- Daily versus as-needed corticosteroids for mild persistent asthma.
Boushey HA, Sorkness CA, King TS, et al. · N Engl J Med 2005 · Clinical Trial, Randomized Controlled Trial
- Safety of leukotriene receptor antagonists in pregnancy.
Bakhireva LN, Jones KL, Schatz M, et al. · J Allergy Clin Immunol 2007 · Clinical Trial, Research Support, Non-U.S. Gov't
- The effects of zafirlukast on capsular contracture: preliminary report.
Scuderi N, Mazzocchi M, Fioramonti P, et al. · Aesthetic Plast Surg 2006 · Clinical Trial
- Comparison of zafirlukast (Accolate) absorption after oral and colonic administration in humans.
Fischer JD, Song MH, Suttle AB, et al. · Pharm Res 2000 · Clinical Trial, Comparative Study
Sponsor: Strides Pharma Intl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.